Jun 23, 2022 / 08:15PM GMT
Operator
Good afternoon, ladies gentlemen, and welcome to the Sarepta Therapeutics SRP-5051 Program Update Conference Call. (Operator Instructions) Reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, President and Chief Executive Officer. Please go ahead.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you, Victor, and thank you all for joining us today as we discuss the clinical hold. In the United States, we're screening and dosing in MOMENTUM, our trial for SRP-5051, our PPMO candidate to treat Duchenne patients amenable to exon 51 skipping.
Let me remind you that we may be making some forward-looking statements today. As we do those, please refer to our public filings for the various risks and uncertainties that come whenever one attempts to make predictions about the future.
Now let me make a few points in advance of Dr. Rodino-Klapac providing real detail on this. First, as you've seen, after a serious adverse event of hypomagnesemia in the trial, the FDA is
Sarepta Therapeutics Inc to Provides Update on SRP-5051 for the Treatment of Duchenne Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers